Reverse the Rollback of the MBTA
Speak out to reinstate critical bird protections under the Migratory Bird Treaty Act.
George S. Golumbeski, of Mendham, NJ, serves as Senior Vice President of Business Development for Celgene Corporation, where he is responsible for forging collaborations with biotechnology companies seeking to bring breakthrough medications to patients suffering from cancer and/or chronic inflammation. In his 25-year career in this sector, George has worked on medications for Parkinson’s disease, epilepsy, cancer, anemia, and Crohn’s disease. He is known globally within the biotechnology industry for his interest in leading-edge science, and his constructiveness in creating inter-company collaborations. George currently serves on the Board of Directors/Trustees of Acceleron Pharma (Cambridge, MA), Enanta Pharmaceuticals (Watertown, MA), and the Keck Graduate Institute (Claremont, CA). He has been a birder since college and currently spends significant time studying and photographing birds. He received a B.A. in Biology from the University of Virginia, a Ph.D. in Genetics from the University of Wisconsin-Madison, and conducted his post-doctoral research in molecular biology at the University of Colorado-Boulder.